Endologix Revenue and Competitors
Estimated Revenue & Valuation
- Endologix's estimated annual revenue is currently $300M per year.
- Endologix's estimated revenue per employee is $765,306
- Endologix's total funding is $210.6M.
Employee Data
- Endologix has 392 Employees.
- Endologix grew their employee count by -6% last year.
Endologix's People
| Name | Title | Email/Phone |
|---|---|---|
1 | COO | Reveal Email/Phone |
2 | Chief Operating Officer | Reveal Email/Phone |
3 | Chief Commercial Officer | Reveal Email/Phone |
4 | EVP Medical, Clinical & Regulatory Affairs | Reveal Email/Phone |
5 | VP, R&D and Program Management | Reveal Email/Phone |
6 | VP, Regulatory Affairs | Reveal Email/Phone |
7 | VP, Health Economics & Reimbursement | Reveal Email/Phone |
8 | VP, Marketing | Reveal Email/Phone |
9 | VP, Quality | Reveal Email/Phone |
10 | VP Engineering | Reveal Email/Phone |
Endologix Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $31800M | 109578 | 4% | $367M | $146B |
What Is Endologix?
Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. The Company\'s PowerLink(TM) System is an endoluminal stent graft (ELG) for treating AAA. AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured abdominal aortic aneurysms is approximately 75%, making it the 13th leading cause of death in the United States.
keywords:Biotechnology
$210.6M
Total Funding
392
Number of Employees
$300M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Endologix News
Endologix Inc., Jotec, Bolton Medical, Braile Biomedica, Cardiatis, Medtronic Plc, Cook Medical, Endospan, Cordis (Cardinal Health),...
Nellix System: Endologix. Nellix is being evaluated for its safety and effectiveness. Nellix EndoVascular Sealing System will be implanted...
Endologix (NSDQ:ELGX) has registered a stock offering of up to $25 million, according to a regulatory filing. The Irvine, Calif.-based company has engaged Piper Jaffray to offer more than 22.2 million shares of common stock at $6.45 per share. Proceeds will be used for manufacturing, clinical t ...
Shares in Endologix (NSDQ:ELGX) slipped by 8% to $6.06 apiece in midday trading today following yesterday’s second-quarter results that beat The Street on earnings expectations and sales. The Irvine, Calif.-based company reported a net loss of $27.1 million or -$1.50 per share on sales of $36.2 ...
Endologix Inc. (NSDQ:ELGX) closed its acquisition of Palo Alto, Calif.-based Nellix. The all-stock deal, which Endologix announced Oct. 27, expands its aortic disorder treatment devices. The Irvine, Calif.-based company said the merger is designed to increase its share of the aortic repair mark ...
Other Companies in Irvine
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $98.9M | 394 | N/A | N/A |
#2 | $50.8M | 406 | 10% | N/A |
#3 | $76.1M | 406 | 14% | N/A |
#4 | $72.4M | 407 | -1% | $550M |
#5 | $74M | 408 | -4% | N/A |